World Diabetes Day:
Diabetes and Well-being

World Diabetes Day

World Diabetes Day (WDD) is observed annually on November 14th, initiated in 1991 by the International Diabetes Federation (IDF) and the World Health Organization (WHO) to raise public awareness about diabetes. This day also commemorates the birthday of Sir Frederick Banting, one of the discoverers of insulin.

The theme for World Diabetes Day in 2024 is “Diabetes and Well-being”,emphasizing that diabetes care should focus on the overall well-being of patients, not just blood glucose levels. It aims to increase awareness of the challenges faced by people with diabetes in their daily lives and encourages a comprehensive approach to improve the quality of life for those affected by diabetes.

1. What is diabetes?

Diabetes is a chronic disease characterized by high blood sugar, resulting from absolute or relative insulin deficiency and impaired insulin utilization. It can be categorized into four types:

1.1 Type 1 Diabetes Mellitus (T1DM)

T1DM is a chronic metabolic endocrine disorder where the pancreas' beta cells are destroyed, leading to an absolute lack of insulin. This destruction is typically mediated by the immune system, which mistakenly attacks and destroys the insulin-producing pancreatic beta cells. Consequently, patients are unable to produce sufficient insulin to maintain normal blood glucose levels. (click "Autoimmune Disease Series: Type 1 Diabetes" for more information)

1.2 Type 2 Diabetes Mellitus (T2DM)

T2DM is the most common form of diabetes, accounting for approximately 90% to 95% of all diabetes cases. Unlike type 1 diabetes, type 2 diabetes is primarily the result of decreased insulin sensitivity (insulin resistance) and a gradual decline in insulin secretion from beta cells. Possible contributing factors include genetics, lifestyle, age, and ethnic or racial background.

1.3 Gestational Diabetes Mellitus (GDM)

GDM refers to the abnormal glucose tolerance first discovered or diagnosed during pregnancy. It typically occurs at any stage of pregnancy but is most often identified in the second or third trimester. The main mechanism of GDM is insulin resistance, which may be caused by a variety of factors including genetics, obesity, poor dietary habits, and lifestyle. Additionally, pregnancy itself increases insulin demand, potentially leading to poor blood glucose control. Women with a history of GDM are at a higher risk of developing type 2 diabetes postpartum.

1.4 Other Specific Types of Diabetes

These are all forms of diabetes caused by factors other than type 1, type 2, or gestational diabetes. Classified by etiology, other specific types can be divided into several subcategories, including monogenic defects in beta cell function, pancreatogenic diabetes, drug- or chemical-induced diabetes, endocrine diseases, monogenic defects in insulin action, genetic syndromes associated with diabetes, infections, and rare forms of immune-mediated diabetes. Among these, monogenic defects in beta cell function and pancreatogenic diabetes are relatively common subcategories.

2. The latest research advancements in diabetes

Currently, scientists have made a series of significant progress in diabetes research, encompassing everything from blood sugar control medications and insulin therapies to innovative diabetes management devices, as well as potential therapies like immunotherapy and beta cell regeneration. Here are some of the latest research developments:

2.1 Pharmacological Advances

SGLT2 inhibitors and GLP-1 receptor agonists, among other novel hypoglycemic drugs, have been proven to effectively lower blood glucose and reduce the risk of cardiovascular complications in patients with type 2 diabetes mellitus (T2DM). The American Diabetes Association (ADA) emphasized the importance of these drugs in its 2024 clinical practice standards [1]. For instance, new drugs like empagliflozin have shown excellent performance in improving blood glucose control in adults with T2DM and have demonstrated potential applications in obesity, cardiovascular risk-related diseases, and diabetic nephropathy.

Additionally, researchers are developing more effective insulin formulations, such as long-acting and rapid-acting insulins, to better mimic the natural secretion pattern of insulin and help patients control blood glucose levels more effectively.

2.2 Disease Classification and Personalized Treatment

Researchers have identified different subtypes of type 2 diabetes, including Severe Insulin Deficiency Diabetes (SIDD), Severe Insulin Resistance Diabetes (SIRD), Mild Obesity-Related Diabetes (MOD), and Mild Age-Related Diabetes (MARD). The identification of these subtypes provides a scientific basis for personalized treatment strategies [2].

2.3 Early Diagnosis and Screening

Early diagnosis and screening of islet autoantibodies are crucial directions in the early diagnosis research of type 1 diabetes, aiding in earlier diagnosis and intervention [3]. The application of continuous glucose monitoring systems (CGM) and automated insulin delivery systems is transforming the management of type 1 diabetes, enhancing patients' self-management abilities and treatment adherence [4]. New devices such as continuous glucose monitors (CGM) and smart insulin pumps can monitor blood glucose levels in real-time and automatically adjust insulin delivery, providing patients with more convenient and efficient management tools.

2.4 Other Research Progress

Recent studies show that non-endocrine tissues can be reprogrammed to respond to blood glucose changes without the use of insulin, offering new possibilities for diabetes treatment. Advances in genomics have deepened our understanding of beta cell function, aiding in the identification of diabetes susceptibility genes and propelling the development of personalized medicine. Analyzing an individual's lipid profile can assess their risk of diabetes and inform the development of corresponding prevention and treatment strategies.

Read more:

Diabetes: What You Need to Know Before Starting Research?

Diabetes and Cardiovascular Disease

3. Diabetes Research Related Products from CUSABIO

To aid in your research of diabetes-related biomarkers and signaling pathways, to comprehend the pathogenesis of diabetes, assess the progression of the disease, and develop novel therapeutic approaches, CUSABIO has meticulously assembled a suite of commonly utilized proteins, antibodies, and ELISA kits in diabetes research. The targets encompass, but are not limited to, insulin (INS) and its receptor (INSR), islet beta cell markers such as GLUT2 and PDX1, inflammatory markers including TNF-α, IL-6, and CRP, oxidative stress markers like 8-OHdG and MDA, and molecules associated with the insulin signaling pathway such as IRS1/2.

● Hot Targets in Diabetes Research

● CUSABIO Recombinant Proteins for Diabetes Research

CSB-MP009438HU1d7 Activity Verified

Measured by its binding ability in a functional ELISA. Immobilized Human GIPR at 2μg/mL can bind Anti-GIPR recombinant antibody (CSB-RA009438MA1HU),the EC50 16.18-18.70 ng/mL.

CSB-MP009514HUb1 Activity Verified

Measured by its binding ability in a functional ELISA. Immobilized Human GLP1R at 2 μg/mL can bind Anti-GLP1R recombinant antibody (CSB-RA009514MA1HU), the EC50 is 54.54-94.23 ng/mL.

CSB-YP011664HU Activity Verified

Measured by its binding ability in a functional ELISA. Immobilized Human IL6 at 2μg/mL can bind Anti-IL6 recombinant antibody (CSB-RA011664MA1HU),the EC50 is 35.80-41.82 ng/mL.

CSB-YP023955HU Activity Verified

Measured by its binding ability in a functional ELISA. Immobilized Human TNF at 5 μg/ml can bind Human TNFR2 protein (CSB-MP023978HU2). The EC50 is 3.470-4.107 ng/mL.

Target Product Name Source Tag Info Product Code
ADIPOQ Recombinant Bovine Adiponectin (ADIPOQ) E.coli N-terminal 6xHis-SUMO-tagged CSB-EP661101BO
Adipoq Recombinant Mouse Adiponectin (Adipoq) E.coli N-terminal 6xHis-tagged CSB-EP723362MO
Adipoq Recombinant Mouse Adiponectin (Adipoq), partial E.coli N-terminal 6xHis-tagged CSB-RP079474m
ADIPOQ Recombinant Bovine Adiponectin (ADIPOQ) Yeast N-terminal 6xHis-tagged CSB-YP661101BO
ADIPOQ Recombinant Horse Adiponectin D (ADIPOQ), partial E.coli Tag-Free CSB-EP4093HO
AKT1 Recombinant Human RAC-alpha serine/threonine-protein kinase (AKT1) E.coli N-terminal GST-tagged CSB-EP001553HU
Akt1 Recombinant Rat RAC-alpha serine/threonine-protein kinase (Akt1) E.coli N-terminal 10xHis-tagged CSB-EP001553RA
Alb Recombinant Mouse Serum albumin (Alb) Baculovirus C-terminal 9xHis-tagged CSB-BP001561MO
ALB Recombinant Dog Serum albumin (ALB) E.coli N-terminal 6xHis-tagged CSB-EP001561DO
ALB Recombinant Macaca fascicularis albumin (ALB) E.coli N-terminal 6xHis-SUMO-tagged CSB-EP001561MOV
ALB Recombinant Macaca fascicularis albumin (ALB) Mammalian cell N-terminal 6xHis-Myc-tagged CSB-MP001561MOV
ALB Recombinant Dog Serum albumin (ALB) Yeast N-terminal 6xHis-tagged CSB-YP001561DO
Alb Recombinant Mouse Albumin (Alb) Yeast N-terminal 6xHis-tagged CSB-YP001561MO
ALB Recombinant Macaca fascicularis albumin (ALB) Yeast N-terminal 6xHis-tagged CSB-YP001561MOV
ALB Recombinant Bovine Serum albumin (ALB) Yeast C-terminal 6xHis-Myc-tagged CSB-YP001561BO
ALB Recombinant Bos taurus Albumin (ALB) Baculovirus C-terminal 6xHis-tagged CSB-BP001561BO
Alb Recombinant Rat Serum albumin (Alb), Biotinylated E.coli N-terminal MBP-tagged and C-terminal 6xHis-Avi-tagged CSB-EP001561RA-B
ALB Recombinant Chicken Serum albumin (ALB), partial Yeast C-terminal 6xHis-tagged CSB-YP001561CH
ALB Recombinant Chicken Albumin (ALB), partial E.coli N-terminal 10xHis-tagged and C-terminal Myc-tagged CSB-EP001561CH
Alb Recombinant Rat Serum albumin (Alb) E.coli N-terminal 6xHis-tagged and C-terminal Avi-tagged CSB-EP001561RA

● CUSABIO Antibodies for Diabetes Research

Phospho-AKT1 (Ser473) Recombinant Monoclonal Antibody
CSB-RA001553A473phHU
CSB-RA001553A473phHU IF

Tested Applications:
ELISA, WB, IHC, IF, IP

SLC2A2 Recombinant Monoclonal Antibody
CSB-RA438622A0HU
CSB-RA438622A0HU FC

Tested Applications:
ELISA, IHC, IF, FC

CRP Monoclonal Antibody
CSB-MA027411E0m
CSB-MA027411E0m IHC

Tested Applications:
ELISA, IHC

DPP4 Antibody
CSB-PA06229A0Rb
CSB-PA06229A0Rb WB

Tested Applications:
ELISA, WB, IHC, IF

- Recombinant Antibody

Target Product Name Species Reactivity Tested Applications Code
AKT1 Phospho-AKT1 (T450) Recombinant Monoclonal Antibody Human ELISA, WB CSB-RA001553A450phHU
AKT1 Phospho-AKT1 (Ser473) Recombinant Monoclonal Antibody Human ELISA, WB, IHC, IF, IP CSB-RA001553A473phHU
AKT1 AKT1 Recombinant Monoclonal Antibody Human, Mouse, Rat ELISA, WB, IHC, IF CSB-RA917625A0HU
ALB ALB Recombinant Monoclonal Antibody Human ELISA, FC CSB-RA264109A0HU
CRP CRP Recombinant Monoclonal Antibody Human ELISA, IHC CSB-RA988767A0HU
DPP4 DPP4 Recombinant Monoclonal Antibody Human ELISA, IHC CSB-RA927191A0HU
GCG GCG Recombinant Monoclonal Antibody Human ELISA CSB-RA009315A0HU
Gipr Gipr Recombinant Monoclonal Antibody Mouse, Rat ELISA CSB-RA009438MA1MO
GIPR GIPR Recombinant Monoclonal Antibody Human ELISA, WB CSB-RA009438MA2HU
GIPR GIPR Recombinant Monoclonal Antibody Human, Macaca fascicularis ELISA CSB-RA009438MA1HU
GLP1R GLP1R Recombinant Monoclonal Antibody Human ELISA CSB-RA009514MA1HU
IL6 IL6 Recombinant Monoclonal Antibody Human ELISA CSB-RA011664MA1HU
INS INS Recombinant Monoclonal Antibody Human ELISA, IHC CSB-RA584163A0HU
INSR INSR Recombinant Monoclonal Antibody Human ELISA, IF CSB-RA155156A0HU
SLC2A2 SLC2A2 Recombinant Monoclonal Antibody Human ELISA, IHC, IF, FC CSB-RA438622A0HU

- Monoclonal Antibody

Target Product Name Species Reactivity Tested Applications Code
ADIPOQ ADIPOQ Monoclonal Antibody Human ELISA CSB-MA079461A0m
AKT1 AKT1 Monoclonal Antibody Human,Mouse,Pig,Rat ELISA, WB CSB-MA011037
ALB ALB Monoclonal Antibody Human ELISA, WB, IHC CSB-MA076752
CRP CRP Monoclonal Antibody Human ELISA, IHC CSB-MA027411E0m
GCG GCG Monoclonal Antibody Human ELISA, IHC CSB-MA935920
IL1B IL1B Monoclonal Antibody Human ELISA CSB-MA065741A0m
IL1B IL1B Monoclonal Antibody Human ELISA, WB, IHC, ICC CSB-MA010884
IL6 IL6 Monoclonal Antibody Human ELISA, WB, IHC CSB-MA067571A0m
PPARG PPARG Monoclonal Antibody Human,Dog,Pig,Rat,Mouse ELISA, WB, ICC CSB-MA930213
TNF TNF Monoclonal Antibody Bovine ELISA CSB-MA084771A0m
TNF TNF Monoclonal Antibody Human,Mouse,Rat ELISA, WB, IHC CSB-MA080271
TNF TNF Monoclonal Antibody Human,Mouse,Rat ELISA, WB, IHC CSB-MA080272

- Polyclonal Antibody

Target Product Name Species Reactivity Tested Applications Code
Adipoq Adipoq Antibody Mouse ELISA CSB-PA07946A0Rb
ADIPOQ ADIPOQ Antibody Human, Mouse ELISA, WB, IHC CSB-PA07956A0Rb
ADIPOQ ADIPOQ Antibody Human ELISA, IHC CSB-PA07957A0Rb
ADIPOQ ADIPOQ Antibody Human, Mouse ELISA, WB, IHC CSB-PA618019YA01HU
ADIPOQ ADIPOQ Antibody Bovine ELISA CSB-PA661101LA01BO
ADIPOQ ADIPOQ Antibody Bovine ELISA, WB CSB-PA661101YA01BO
ADIPOQ ADIPOQ Antibody Human ELISA, WB CSB-PA000014
ADIPOQ ADIPOQ Antibody Human, Mouse, Rat ELISA, WB CSB-PA000806
ADIPOQ ADIPOQ Antibody Human, Mouse ELISA, IHC CSB-PA293186
ADIPOQ ADIPOQ Antibody Human, Mouse ELISA, WB CSB-PA149289
ADIPOQ ADIPOQ Antibody Human, Mouse ELISA, WB CSB-PA938581
ADIPOQ ADIPOQ Antibody Human, Mouse, Rat ELISA, WB CSB-PA828343
AKT1 AKT1 Antibody Human ELISA, WB, IHC, IF, IP CSB-PA15905A0Rb
AKT1 AKT1 Antibody Human, Mouse, Rat ELISA, WB, IHC, IF CSB-PA000852
AKT1 Phospho-AKT1 (S124) Antibody Human, Mouse, Rat ELISA, WB, IHC CSB-PA008118
AKT1 Phospho-AKT1 (T72) Antibody Human, Mouse, Rat ELISA, WB, IHC CSB-PA008120
AKT1 AKT1 Antibody Human, Mouse, Rat ELISA, IHC CSB-PA008122
AKT1 AKT1 Antibody Human, Mouse, Rat WB CSB-PA080256
AKT1 Phospho-AKT1 (S129) Antibody Human, Mouse, Rat ELISA, WB CSB-PA000645
AKT1 Phospho-AKT1 (T308) Antibody Human, Mouse, Rat ELISA, WB CSB-PA000657

● CUSABIO ELISA Kits for Diabetes Research

CSB-E11987r standard curves

Rat TNF-α ELISA kit
CSB-E11987r

460 Citations

CSB-E04640r standard curves

Rat IL-6 ELISA KIT
CSB-E04640r

339 Citations

CSB-E08055r standard curves

Rat IL-1β ELISA Kit
CSB-E08055r

267 Citations

CSB-E05071m standard curves

Mouse INS ELISA Kit
CSB-E05071m

115 Citations

Target Product Name Sample Types Detection Range Code
ADIPOQ Bovine adiponectin,ADP ELISA Kit serum, plasma, tissue homogenates 3.125 μg/mL-50 μg/mL CSB-E14054B
ADIPOQ Sheep adiponectin (ADIPOQ)ELISA kit serum, plasma 6.25 ng/mL-100 ng/mL CSB-EL001366SH
ADIPOQ Hamster adiponectin, C1Q and collagen domain containing (ADIPOQ)ELISA kit serum, plasma, tissue homogenates 0.469 ng/mL-30 ng/mL CSB-EL001366HA
AKT1 Human RAC-alpha serine/threonine-protein kinase(AKT1) ELISA kit serum, plasma, cell lysates 0.312 ng/mL-20 ng/mL CSB-EL001553HU
ALB Mouse Albumin (Alb)ELISA Kit serum, plasma, tissue homogenates 0.781 μg/mL-200 μg/mL CSB-E13878m
ALB Pig Albumin (Alb) ELISA Kit serum, plasma, urine 0.03 μg/mL-7000 μg/mL CSB-E16207p
ALB Goat Albumin (Alb)ELISA Kit serum, plasma, tissue homogenates 0.17 μg/mL-350 μg/mL CSB-E15758G
ALB Dog Albumin(Alb) ELISA Kit serum, plasma, tissue homogenates 0.273 μg/mL-35 μg/mL CSB-E15757c
ALB Sheep Albumin (Alb)ELISA Kit serum, plasma, cell culture supernates,Urine, Tissue Homogenates 350 μg/mL-21.88 μg/mL CSB-E15839Sh
ALB Bovine Albumin(Alb) ELISA kit serum, plasma, tissue homogenates 0.313 μg/mL-80 μg/mL CSB-E08664b
ALB Horse Albumin(Alb) ELISA Kit serum, plasma 1.25 μg/mL-80 μg/mL CSB-E16205Hs
ALB Guinea Pig Albumin(Alb) ELISA kit serum, plasma, tissue homogenates 0.156 μg/mL-10 μg/mL CSB-E15765Gp
ALB Rabbit Albumin(Alb) ELISA Kit serum, plasma, urine 0.273 μg/mL-70 μg/mL CSB-E16204Rb
CRP Rat C-Reactive Protein,CRP ELISA Kit serum, plasma, cell culture supernates, tissue homogenates, cell lysates 31.25 ng/mL-2000 ng/mL CSB-E07922r
CRP Mouse C-Reactive Protein,CRP ELISA Kit serum, plasma, cell culture supernates, tissue homogenates 15.6 ng/mL-1000 ng/mL CSB-E07923m
CRP Rabbit C-Reactive Protein,CRP ELISA Kit serum, plasma 7.8 pg/mL-2000 pg/mL CSB-E06847Rb
CRP Pig C-reactive protein,CRP ELISA Kit serum, plasma, tissue homogenates 0.625 ng/mL-40 ng/mL CSB-E08163p
CRP Canine C-Reactive Protein,CRP ELISA Kit serum, plasma, cell culture supernates 0.312 μg/mL-20 μg/mL CSB-E14262c
CRP Mouse C-Reactive Protein,CRP ELISA Kit serum, plasma, tissue homogenates 5 ng/mL-4000 ng/mL CSB-E07923m(1)
CRP Bovine C-reactive protein,CRP ELISA Kit serum, plasma 1.25 ng/mL-80 ng/mL CSB-E08577b

Reference:

[1] Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care, 2024.

[2] Translating Subphenotypes of Newly Diagnosed Type 2 Diabetes from Cohort Studies to Electronic Health Records in the United States. medRxiv, 2024.

[3] Islet Autoantibody Levels Differentiate Progression Trajectories in Individuals With Presymptomatic Type 1 Diabetes. Diabetes, 2022.

[4] Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control. Diabetes Metab J, 2023.

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1